Please login to the form below
Nippon Shinyaku
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Nippon Shinyaku's Japan sales performance.
FDA sets Q3 decision date for NS Pharma’s DMD drug
NS Pharma and its parent company Nippon Shinyaku are currently enrolling patients for a phase 3 study in Japan and the US – named RACER53.
Wave’s challenge to Sarepta in Duchenne falls flat
The demise of Wave’s programmes leaves Japan’s Nippon Shinyaku Pharma as the main rival to Sarepta in DMD.
Solid Bio falls as FDA halts DMD trial over safety concerns
In the meantime, rival candidate viltolarsen from Japanese pharma Nippon Shinyaku (NS Pharma) has been filed with the FDA for the treatment of DMD.
Sarepta rival NS Pharma files Duchenne drug with FDA
Another blow for Sarepta following FDA rejection earlier this year. Japanese pharma Nippon Shinyaku (NS Pharma) has announced its candidate for Duchenne musuclar dystrophy (DMD) has been submitted to the FDA
Biosimilar Remicade reaches market in Japan and India
India. In Japan, Nippon Kayaku has launched a biosimilar version of Remicade (infliximab) originally developed by South Korean biotechnology company Celltrion, which was approved for marketing in July. ... Nippon Kayaku said infliximab is the second
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Biogen delays filing of Alzheimer’s drug, which hits its share price
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Alnylam and Vir plan gene-silencing attack on COVID-19 virus
- Merck’s Keytruda hits the mark in triple negative breast cancer
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Lilly starts world first trial of an antibody drug for COVID-19
- Pfizer’s Ibrance misses the mark in early breast cancer
- Rise of the patient influencer
- Working together against COVID-19
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
PMHub
Porterhouse Medical Group
The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
